Analysis of the efficacy of adjusting the dose of imatinib with therapeutic drug monitoring in adjuvant treatment after complete resection of gastrointestinal stromal tumors

This study assessed the impact of therapeutic drug monitoring (TDM)-guided dose adjustments of imatinib in 70 gastrointestinal stromal tumor patients receiving adjuvant therapy after tumor resection. Dose reduction improved adverse reaction rates, physical and mental health scores, and maintained high recurrence-free survival (92.8%) and overall survival (100%) over three years.